METTL3 and glioblastoma: Intriguingly, SRSF7 has been demonstrated to be a novel m6A regulator, which exerts a tumorigenic effect in glioblastoma via its modulation of m6A sites on PDZ-binding kinase, and via binding by the m6A reader IGF2BP2 [82].